What is HC Wainwright’s Estimate for DYN Q2 Earnings?

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Research analysts at HC Wainwright issued their Q2 2027 EPS estimates for Dyne Therapeutics in a research report issued to clients and investors on Friday, November 6th. HC Wainwright analyst A. Ghosh forecasts that the company will post earnings per share of ($1.00) for the quarter. HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q3 2027 earnings at ($0.92) EPS, Q4 2027 earnings at ($0.62) EPS and FY2030 earnings at $0.84 EPS.

Several other equities analysts have also issued reports on DYN. Robert W. Baird decreased their price objective on Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research report on Wednesday, September 9th. Jefferies Financial Group reissued a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, September 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Thursday, October 15th. Piper Sandler reaffirmed an “overweight” rating and issued a $47.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, September 29th. Finally, Oppenheimer lowered shares of Dyne Therapeutics from an “outperform” rating to a “market perform” rating and cut their price target for the company from $40.00 to $15.00 in a research note on Wednesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $31.29.

Dyne Therapeutics Trading Up 3.0%

NASDAQ DYN opened at $18.62 on Monday. The firm has a market cap of $3.48 billion, a P/E ratio of -5.13 and a beta of 1.22. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. The stock’s 50-day moving average is $17.57 and its 200-day moving average is $19.34. Dyne Therapeutics has a one year low of $14.00 and a one year high of $27.31.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Thursday, November 5th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.15). During the same period in the previous year, the company posted ($0.76) earnings per share.

Institutional Investors Weigh In On Dyne Therapeutics

Several institutional investors have recently bought and sold shares of DYN. Russell Investments Group Ltd. boosted its position in Dyne Therapeutics by 141.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 255,190 shares of the company’s stock worth $4,111,000 after acquiring an additional 149,637 shares during the last quarter. Pictet Asset Management Holding SA raised its holdings in shares of Dyne Therapeutics by 7.4% in the third quarter. Pictet Asset Management Holding SA now owns 20,805 shares of the company’s stock valued at $335,000 after purchasing an additional 1,433 shares during the last quarter. Alps Advisors Inc. raised its holdings in shares of Dyne Therapeutics by 48.1% in the third quarter. Alps Advisors Inc. now owns 247,403 shares of the company’s stock valued at $3,986,000 after purchasing an additional 80,321 shares during the last quarter. CenterBook Partners LP raised its holdings in shares of Dyne Therapeutics by 167.7% in the third quarter. CenterBook Partners LP now owns 57,650 shares of the company’s stock valued at $929,000 after purchasing an additional 36,112 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Dyne Therapeutics in the third quarter valued at approximately $154,000. Institutional investors own 96.68% of the company’s stock.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, insider Douglas Kerr sold 3,745 shares of Dyne Therapeutics stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $24.35, for a total value of $91,190.75. Following the sale, the insider owned 163,854 shares of the company’s stock, valued at $3,989,844.90. This trade represents a 2.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Cox sold 5,658 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total value of $106,823.04. Following the completion of the sale, the chief executive officer owned 357,507 shares in the company, valued at approximately $6,749,732.16. This trade represents a 1.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 2,598,706 shares of company stock worth $65,432,671 in the last 90 days. Company insiders own 9.46% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue.

The company’s programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy.